\ The extension of the supply contract will run from March 31, 2024, to April 30, 2025.

TDB keeps you informed. Follow us on Facebook, Twitter and Instagram

Health allocates nearly 2 million euros

\ The budget for the acquisition of this conjugated vaccine amounts to 1.961.024 €.

The Consell de Govern has authorized the extension of the contract for the supply of the conjugate vaccine of twenty serotypes against pneumococcus from March 31, 2024, to April 30, 2025, for a total estimated value of 1,961,024 €, according to the following annual budget distribution: 1,470,768 € for 2024 and 490,256 € for 2025.

Pneumococcal pneumonia and invasive pneumococcal disease (IPD) are a major health problem associated mainly with the existence of risk factors and age. In Spain, in recent years, the National Epidemiological Surveillance Network (RENAVE) has recorded between three thousand and four thousand cases per year of these diseases, which mainly affect children under five years of age and the elderly.

Vaccination is a fundamental tool to prevent invasive pneumococcal disease and, for this reason, in 2016 the vaccine was included in the children’s calendar. In the case of older people, the vaccine was already administered to people in risk groups, and in 2018 the Public Health Commission approved universal vaccination at 65 years of age.

In 2022, a new twenty-serotype conjugate vaccine (VNC20) was licensed for the adult population, covering practically the same spectrum of pneumococcal serotypes as the previous ones (especially those of greatest concern in terms of the impact of the disease), whose technology significantly improves the response and, therefore, protection.